These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11029473)

  • 21. [Renoprotective effects of ACE inhibitors and AT1 antagonists on diabetic nephropathy beyond blood pressure control].
    Shionoiri H; Yasuda G; Takizawa T; Shionoiri F
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():394-9. PubMed ID: 15999741
    [No Abstract]   [Full Text] [Related]  

  • 22. [Diabetic nephropathy].
    Koya D; Kashiwagi A
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():625-9. PubMed ID: 15779451
    [No Abstract]   [Full Text] [Related]  

  • 23. Angiotensin receptor blockers--finally the evidence is coming in: IDNT and RENAAL.
    Dickstein K
    Int J Cardiol; 2002 Dec; 86(2-3):325-6. PubMed ID: 12419573
    [No Abstract]   [Full Text] [Related]  

  • 24. [Renoprotective effect of Blood pressure control on progression of diabetic retinopathies].
    Katayama S
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():389-93. PubMed ID: 15999740
    [No Abstract]   [Full Text] [Related]  

  • 25. Diabetic nephropathy.
    Goto A
    N Engl J Med; 2002 Sep; 347(12):947-8; author reply 947-8. PubMed ID: 12239270
    [No Abstract]   [Full Text] [Related]  

  • 26. Use of angiotensin-converting enzyme inhibitors in patients with diabetic nephropathy.
    How HY; Sibai BM
    J Matern Fetal Neonatal Med; 2002 Dec; 12(6):402-7. PubMed ID: 12683651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin receptors blockers are preferred to angiotensin-converting inhibitors [corrected].
    Feldman L; Weissgarten J
    Isr Med Assoc J; 2004 May; 6(5):299-300. PubMed ID: 15151374
    [No Abstract]   [Full Text] [Related]  

  • 28. ACE inhibitor use and the long-term risk of renal failure in diabetics.
    Woo KT; Lau YK; Wong KS; Chan CM
    Kidney Int; 2006 Oct; 70(7):1376-7; author reply 1378. PubMed ID: 16988741
    [No Abstract]   [Full Text] [Related]  

  • 29. Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?
    Sternlicht H; Bakris GL
    Blood Purif; 2016; 41(1-3):139-43. PubMed ID: 26766168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antihypertensive therapy for the prevention of nephropathy in diabetic hypertensive patients.
    Isaacs AN; Vincent A
    J Clin Pharm Ther; 2016 Apr; 41(2):111-5. PubMed ID: 26850093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renoprotection with antihypertensive agents.
    Hilgers KF; Mann JF
    Lancet; 2002 May; 359(9318):1693; author reply 1693-4. PubMed ID: 12020551
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical practice. Nephropathy in patients with type 2 diabetes.
    Remuzzi G; Schieppati A; Ruggenenti P
    N Engl J Med; 2002 Apr; 346(15):1145-51. PubMed ID: 11948275
    [No Abstract]   [Full Text] [Related]  

  • 33. [Diabetic nephropathy].
    Haneda M
    Nihon Rinsho; 2002 Oct; 60 Suppl 10():260-9. PubMed ID: 12430239
    [No Abstract]   [Full Text] [Related]  

  • 34. [Protective effect of antihypertensive agents on renal insufficiency (REIN, RENAAL, IDNT, AASK, etc)].
    Tsuchida H; Kimura K
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():617-22. PubMed ID: 15171445
    [No Abstract]   [Full Text] [Related]  

  • 35. 1999 WHO/ISH Hypertension Guidelines--highlights & ESH update.
    Kjeldsen SE; Erdine S; Farsang C; Sleight P; Mancia G;
    J Hypertens; 2002 Jan; 20(1):153-5. PubMed ID: 11791039
    [No Abstract]   [Full Text] [Related]  

  • 36. The CARI guidelines. Cost-effectiveness and socioeconomic implications of prevention and management of chronic kidney disease in type 2 diabetes.
    Chadban S; Howell M; Twigg S; Thomas M; Jerums G; Cass A; Campbell D; Nicholls K; Tong A; Mangos G; Stack A; MacIsaac RJ; Girgis S; Colagiuri R; Colagiuri S; Craig J;
    Nephrology (Carlton); 2010 Apr; 15 Suppl 1():S195-203. PubMed ID: 20591031
    [No Abstract]   [Full Text] [Related]  

  • 37. Role of angiotensin II in the progression of diabetic nephropathy-therapeutic implications.
    Wiecek A; Chudek J; Kokot F
    Nephrol Dial Transplant; 2003 Jul; 18 Suppl 5():v16-20. PubMed ID: 12817060
    [No Abstract]   [Full Text] [Related]  

  • 38. The road to renal failure: an overview of diabetic nephropathy.
    McCrary EB
    Adv Nurse Pract; 2008 Jul; 16(7):61-3. PubMed ID: 19181161
    [No Abstract]   [Full Text] [Related]  

  • 39. [Role of the renin-angiotensin system in the pathogenesis, clinical picture and treatment of diabetic nephropathy].
    Wittmann I; Degrell P; Komáromy A; Molnár GA; Wagner Z; Wagner L; Mazák I; Nagy J
    Orv Hetil; 2003 Mar; 144(13):613-9. PubMed ID: 12728786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calcium channel blockers in the prevention of end stage renal disease: a review.
    Derwa A; Peeters P; Vanholder R
    Acta Clin Belg; 2004; 59(1):44-56. PubMed ID: 15065696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.